Cell and gene therapies are considered highly innovative but also challenging approaches in modern cardiology. While early hopes for adult stem cells from bone marrow or skeletal muscle were largely disappointed, pluripotent stem cells and gene editing methods are now coming into focus. Results from preclinical studies are encouraging, but have not (yet) been confirmed to the same extent in clinical trials. The main problems are immunological issues, arrhythmia risks, costs, lack of reproducibility and, in some cases, ethical concerns. Future developments, including advanced gene editing without double-strand breaks (base/prime editing) or targeted epigenetic modulation, promise to further develop the potential of regenerative medicine in the field of cardiology.
Autoren
- Tanja Schliebe
Publikation
- CARDIOVASC
Related Topics
You May Also Like
- Update on diagnostics, risk stratification and therapy
Acute myeloid leukemia 2025
- New practice guideline for fibromyalgia syndrome
Good times, bad times
- Findings from the TRACK-FA study
Neuroimaging biomarkers in Friedreich’s ataxia
- Doing sport without fear or risk
Doing sport without fear or risk
- Chronic inducible urticaria
What has stayed the same, what has changed?
- National Health Report 2025
Mental health in Switzerland
- Blastic plasmacytoid dendritic cell neoplasia
Rare malignancy from a dermatological perspective
- Prevention of skin cancer